The similarity of the pharmacophore models derived from different target complexes suggests that it is fairly possible to obtain a multi-target structure, which could exhibit the desired activity on MAO-B, SERT, 5-HT1AR, and D2R, devoid of possible side effects, and potentially alleviate symptoms such as depression and motor dysfunctions. This evidence concerns the gene SLC6A4 and depressive disorder.